News and Breakthroughs

Lurie Cancer Center at Northwestern Memorial Hospital is ranked No. 6 in the nation by U.S. News & World Report in its 2021-2022 list of Best Hospitals for Cancer, and recognized once again as the top Cancer program in Illinois and Chicago.

A targeted virtual health intervention was effective in reducing fear of recurrence among breast cancer survivors.

A Northwestern Medicine study has found that women with hormone receptor-positive breast cancer were more likely to discontinue hormone therapy early due to poor quality of life-related outcomes.

Seth Pollack, MD, a renowned expert on immunotherapy strategies, is the new director of Lurie Cancer Center’s Sarcoma Program.

On Sunday, June 6, our 28th Annual Cancer Survivors’ Celebration & Walk brought us together, virtually, to celebrate milestones, advance life-changing research, and honor those who have faced or are facing cancer.

In 1991, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University was dedicated through a gift of endowment from Ann and Robert H. Lurie. We proudly commemorate and recognize this important date in Lurie Cancer Center’s history by celebrating the 30th anniversary of its naming throughout the year 2021.

For the first time, scientists have examined how the three-dimensional structure of chromatin can play a part in the development of bladder cancer and pediatric brain tumors, according to a pair of Northwestern Medicine studies.

Using small molecular inhibitors to block the BAP1 complex may be a promising targeted therapy approach for leukemia, according to a Northwestern Medicine study published in Nature Cancer.

Every year, on May 20, Clinical Trials Day is celebrated around the world. COVID-19 made 2020 an extraordinary and challenging time – but clinical investigators rose to the challenge. Thanks to clinical trials, millions of doses of life-saving vaccines have been developed and administered around the world, giving reason to hope for a better year ahead.

Two Northwestern Medicine studies are improving the understanding of epigenetic mechanisms in cancer development and progression, and identifying novel cancer driver genes that may help identify patients who will benefit from immunotherapy.